ID   PDE3B_HUMAN             Reviewed;        1112 AA.
AC   Q13370; B7ZM37; O00639; Q14408; Q6SEI4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=cGMP-inhibited 3',5'-cyclic phosphodiesterase B;
DE            EC=3.1.4.17;
DE   AltName: Full=CGIPDE1;
DE            Short=CGIP1;
DE   AltName: Full=Cyclic GMP-inhibited phosphodiesterase B;
DE            Short=CGI-PDE B;
GN   Name=PDE3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Adipose tissue;
RX   PubMed=8884271; DOI=10.1006/geno.1996.0493;
RA   Miki T., Taira M., Hockman S., Shimada F., Lieman J., Napolitano M.,
RA   Ward D., Taira M., Makino H., Manganiello V.C.;
RT   "Characterization of the cDNA and gene encoding human PDE3B, the cGIP1
RT   isoform of the human cyclic GMP-inhibited cyclic nucleotide
RT   phosphodiesterase family.";
RL   Genomics 36:476-485(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8706823; DOI=10.1016/0014-5793(96)00410-3;
RA   Murata T., Taira M., Manganiello V.C.;
RT   "Differential expression of cGMP-inhibited cyclic nucleotide
RT   phosphodiesterases in human hepatoma cell lines.";
RL   FEBS Lett. 390:29-33(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-87.
RX   PubMed=8921398; DOI=10.1006/geno.1996.0544;
RA   Loebbert R.W., Winterpacht A., Seipel B., Zabel B.U.;
RT   "Molecular cloning and chromosomal assignment of the human homologue
RT   of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A) -- a gene
RT   involved in fat metabolism located at 11p15.1.";
RL   Genomics 37:211-218(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=16702214; DOI=10.1074/jbc.M601307200;
RA   Liu H., Tang J.R., Choi Y.H., Napolitano M., Hockman S., Taira M.,
RA   Degerman E., Manganiello V.C.;
RT   "Importance of cAMP-response element-binding protein in regulation of
RT   expression of the murine cyclic nucleotide phosphodiesterase 3B
RT   (Pde3b) gene in differentiating 3T3-L1 preadipocytes.";
RL   J. Biol. Chem. 281:21096-21113(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-442, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   FUNCTION, INTERACTION WITH RAPGEF3 AND PIK3R6, AND MUTAGENESIS OF
RP   ARG-2; ARG-3; ARG-6; ALA-8; LYS-9; ALA-10; ARG-12; ARG-439; ARG-440;
RP   SER-445 AND PRO-449.
RX   PubMed=21393242; DOI=10.1074/jbc.M110.217026;
RA   Wilson L.S., Baillie G.S., Pritchard L.M., Umana B., Terrin A.,
RA   Zaccolo M., Houslay M.D., Maurice D.H.;
RT   "A phosphodiesterase 3B-based signaling complex integrates exchange
RT   protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals
RT   in human arterial endothelial cells.";
RL   J. Biol. Chem. 286:16285-16296(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-442, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 654-1073 IN COMPLEX WITH
RP   METAL IONS AND INHIBITORS, FUNCTION, AND COFACTOR.
RX   PubMed=15147193; DOI=10.1021/bi049868i;
RA   Scapin G., Patel S.B., Chung C., Varnerin J.P., Edmondson S.D.,
RA   Mastracchio A., Parmee E.R., Singh S.B., Becker J.W.,
RA   Van der Ploeg L.H., Tota M.R.;
RT   "Crystal structure of human phosphodiesterase 3B: atomic basis for
RT   substrate and inhibitor specificity.";
RL   Biochemistry 43:6091-6100(2004).
CC   -!- FUNCTION: Cyclic nucleotide phosphodiesterase with a dual-
CC       specificity for the second messengers cAMP and cGMP, which are key
CC       regulators of many important physiological processes. May play a
CC       role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through
CC       simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling
CC       complex in which the PI3K gamma complex is activated by RAPGEF3
CC       and which is involved in angiogenesis.
CC       {ECO:0000269|PubMed:15147193, ECO:0000269|PubMed:21393242}.
CC   -!- CATALYTIC ACTIVITY: Nucleoside 3',5'-cyclic phosphate + H(2)O =
CC       nucleoside 5'-phosphate.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000269|PubMed:15147193};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000269|PubMed:15147193};
CC   -!- ENZYME REGULATION: Inhibited by cGMP.
CC   -!- SUBUNIT: Interacts with PIK3CG (By similarity). Interacts with
CC       RAPGEF3 and PIK3R6. {ECO:0000250, ECO:0000269|PubMed:15147193,
CC       ECO:0000269|PubMed:21393242}.
CC   -!- INTERACTION:
CC       P48736:PIK3CG; NbExp=3; IntAct=EBI-6172856, EBI-1030384;
CC       Q5UE93:PIK3R6; NbExp=3; IntAct=EBI-6172856, EBI-6172907;
CC       O95398:RAPGEF3; NbExp=8; IntAct=EBI-6172856, EBI-6172806;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13370-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13370-2; Sequence=VSP_054138;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundant in adipose tissues.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. PDE3 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U38178; AAC50724.1; -; Genomic_DNA.
DR   EMBL; D50640; BAA09306.1; -; Genomic_DNA.
DR   EMBL; X95520; CAA64774.1; -; mRNA.
DR   EMBL; AY459346; AAR24292.1; -; mRNA.
DR   EMBL; AC018795; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090835; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68474.1; -; Genomic_DNA.
DR   EMBL; BC136565; AAI36566.1; -; mRNA.
DR   EMBL; BC136566; AAI36567.1; -; mRNA.
DR   EMBL; BC144248; AAI44249.1; -; mRNA.
DR   CCDS; CCDS7817.1; -. [Q13370-1]
DR   PIR; S70522; S70522.
DR   RefSeq; NP_000913.2; NM_000922.3. [Q13370-1]
DR   UniGene; Hs.445711; -.
DR   PDB; 1SO2; X-ray; 2.40 A; A/B/C/D=654-1073.
DR   PDB; 1SOJ; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=654-1073.
DR   PDBsum; 1SO2; -.
DR   PDBsum; 1SOJ; -.
DR   ProteinModelPortal; Q13370; -.
DR   SMR; Q13370; -.
DR   BioGrid; 111166; 27.
DR   IntAct; Q13370; 5.
DR   STRING; 9606.ENSP00000282096; -.
DR   BindingDB; Q13370; -.
DR   ChEMBL; CHEMBL290; -.
DR   DrugBank; DB07954; 3-isobutyl-1-methyl-7H-xanthine.
DR   DrugBank; DB00201; Caffeine.
DR   GuidetoPHARMACOLOGY; 1299; -.
DR   iPTMnet; Q13370; -.
DR   PhosphoSitePlus; Q13370; -.
DR   BioMuta; PDE3B; -.
DR   DMDM; 143811435; -.
DR   EPD; Q13370; -.
DR   MaxQB; Q13370; -.
DR   PaxDb; Q13370; -.
DR   PeptideAtlas; Q13370; -.
DR   PRIDE; Q13370; -.
DR   Ensembl; ENST00000282096; ENSP00000282096; ENSG00000152270. [Q13370-1]
DR   Ensembl; ENST00000455098; ENSP00000388644; ENSG00000152270. [Q13370-2]
DR   GeneID; 5140; -.
DR   KEGG; hsa:5140; -.
DR   UCSC; uc001mln.4; human. [Q13370-1]
DR   CTD; 5140; -.
DR   DisGeNET; 5140; -.
DR   GeneCards; PDE3B; -.
DR   HGNC; HGNC:8779; PDE3B.
DR   HPA; HPA056111; -.
DR   MIM; 602047; gene.
DR   neXtProt; NX_Q13370; -.
DR   OpenTargets; ENSG00000152270; -.
DR   PharmGKB; PA33127; -.
DR   eggNOG; ENOG410IEGG; Eukaryota.
DR   eggNOG; ENOG410XT2V; LUCA.
DR   GeneTree; ENSGT00760000119066; -.
DR   HOGENOM; HOG000060144; -.
DR   HOVERGEN; HBG053541; -.
DR   KO; K13296; -.
DR   OMA; CAFFFLT; -.
DR   OrthoDB; EOG091G0BTI; -.
DR   PhylomeDB; Q13370; -.
DR   TreeFam; TF329631; -.
DR   BRENDA; 3.1.4.17; 2681.
DR   Reactome; R-HSA-165160; PDE3B signalling.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   SignaLink; Q13370; -.
DR   SIGNOR; Q13370; -.
DR   ChiTaRS; PDE3B; human.
DR   EvolutionaryTrace; Q13370; -.
DR   GenomeRNAi; 5140; -.
DR   PRO; PR:Q13370; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000152270; -.
DR   CleanEx; HS_PDE3B; -.
DR   Genevisible; Q13370; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:BHF-UCL.
DR   GO; GO:0032045; C:guanyl-nucleotide exchange factor complex; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; EXP:Reactome.
DR   GO; GO:0004119; F:cGMP-inhibited cyclic-nucleotide phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043422; F:protein kinase B binding; ISS:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006198; P:cAMP catabolic process; IEP:BHF-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:BHF-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; TAS:BHF-UCL.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IC:BHF-UCL.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IMP:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF00233; PDEase_I; 1.
DR   SMART; SM00471; HDc; 1.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; cAMP; cGMP;
KW   Complete proteome; Hydrolase; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1112       cGMP-inhibited 3',5'-cyclic
FT                                phosphodiesterase B.
FT                                /FTId=PRO_0000198802.
FT   TRANSMEM     88    108       Helical. {ECO:0000255}.
FT   TRANSMEM    117    137       Helical. {ECO:0000255}.
FT   TRANSMEM    152    172       Helical. {ECO:0000255}.
FT   TRANSMEM    192    212       Helical. {ECO:0000255}.
FT   TRANSMEM    220    240       Helical. {ECO:0000255}.
FT   TRANSMEM    247    267       Helical. {ECO:0000255}.
FT   REGION        1     25       Interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   REGION      436    460       Interaction with PIK3R6.
FT                                {ECO:0000269|PubMed:21393242}.
FT   REGION      713   1072       Catalytic. {ECO:0000250}.
FT   COMPBIAS   1077   1080       Poly-Glu.
FT   ACT_SITE    737    737       Proton donor. {ECO:0000250}.
FT   METAL       741    741       Divalent metal cation 1.
FT   METAL       821    821       Divalent metal cation 1.
FT   METAL       822    822       Divalent metal cation 1.
FT   METAL       822    822       Divalent metal cation 2.
FT   METAL       937    937       Divalent metal cation 1.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61409}.
FT   MOD_RES     295    295       Phosphoserine; by PKB/AKT1 or PKB/AKT2.
FT                                {ECO:0000250}.
FT   MOD_RES     296    296       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61409}.
FT   MOD_RES     442    442       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     376    426       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054138.
FT   VARIANT      87     87       A -> V (in dbSNP:rs1056584).
FT                                {ECO:0000269|PubMed:8921398}.
FT                                /FTId=VAR_031462.
FT   MUTAGEN       2      2       R->A: Abolishes interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN       3      3       R->A: Abolishes interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN       6      6       R->A: Abolishes interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN       8      8       A->D: Impairs interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN       9      9       K->A: Abolishes interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN      10     10       A->D: Impairss interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN      12     12       R->A: Abolishes interaction with RAPGEF3.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN     439    439       R->A: Impairss interaction with PIK3R6.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN     440    440       R->A: Impairss interaction with PIK3R6.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN     445    445       S->A: Impairss interaction with PIK3R6.
FT                                {ECO:0000269|PubMed:21393242}.
FT   MUTAGEN     449    449       P->A: Impairss interaction with PIK3R6.
FT                                {ECO:0000269|PubMed:21393242}.
FT   CONFLICT     84     84       A -> D (in Ref. 1; AAC50724 and 2;
FT                                BAA09306). {ECO:0000305}.
FT   HELIX       662    674       {ECO:0000244|PDB:1SO2}.
FT   HELIX       681    688       {ECO:0000244|PDB:1SO2}.
FT   HELIX       689    694       {ECO:0000244|PDB:1SO2}.
FT   HELIX       695    706       {ECO:0000244|PDB:1SO2}.
FT   HELIX       709    712       {ECO:0000244|PDB:1SO2}.
FT   HELIX       717    728       {ECO:0000244|PDB:1SO2}.
FT   STRAND      735    738       {ECO:0000244|PDB:1SO2}.
FT   HELIX       739    752       {ECO:0000244|PDB:1SO2}.
FT   HELIX       802    804       {ECO:0000244|PDB:1SO2}.
FT   HELIX       808    820       {ECO:0000244|PDB:1SO2}.
FT   TURN        821    824       {ECO:0000244|PDB:1SO2}.
FT   HELIX       830    835       {ECO:0000244|PDB:1SO2}.
FT   HELIX       839    843       {ECO:0000244|PDB:1SO2}.
FT   TURN        844    846       {ECO:0000244|PDB:1SO2}.
FT   HELIX       849    863       {ECO:0000244|PDB:1SO2}.
FT   HELIX       866    868       {ECO:0000244|PDB:1SO2}.
FT   TURN        870    873       {ECO:0000244|PDB:1SO2}.
FT   HELIX       876    891       {ECO:0000244|PDB:1SO2}.
FT   HELIX       895    897       {ECO:0000244|PDB:1SO2}.
FT   HELIX       898    909       {ECO:0000244|PDB:1SO2}.
FT   STRAND      911    913       {ECO:0000244|PDB:1SO2}.
FT   HELIX       922    937       {ECO:0000244|PDB:1SO2}.
FT   HELIX       940    942       {ECO:0000244|PDB:1SO2}.
FT   HELIX       945    968       {ECO:0000244|PDB:1SO2}.
FT   HELIX       984    994       {ECO:0000244|PDB:1SO2}.
FT   HELIX       996   1005       {ECO:0000244|PDB:1SO2}.
FT   STRAND     1012   1015       {ECO:0000244|PDB:1SOJ}.
FT   STRAND     1055   1058       {ECO:0000244|PDB:1SO2}.
FT   HELIX      1060   1072       {ECO:0000244|PDB:1SO2}.
SQ   SEQUENCE   1112 AA;  124333 MW;  55451C3DA142EF6A CRC64;
     MRRDERDAKA MRSLQPPDGA GSPPESLRNG YVKSCVSPLR QDPPRGFFFH LCRFCNVELR
     PPPASPQQPR RCSPFCRARL SLGALAAFVL ALLLGAEPES WAAGAAWLRT LLSVCSHSLS
     PLFSIACAFF FLTCFLTRTK RGPGPGRSCG SWWLLALPAC CYLGDFLVWQ WWSWPWGDGD
     AGSAAPHTPP EAAAGRLLLV LSCVGLLLTL AHPLRLRHCV LVLLLASFVW WVSFTSLGSL
     PSALRPLLSG LVGGAGCLLA LGLDHFFQIR EAPLHPRLSS AAEEKVPVIR PRRRSSCVSL
     GETAASYYGS CKIFRRPSLP CISREQMILW DWDLKQWYKP HYQNSGGGNG VDLSVLNEAR
     NMVSDLLTDP SLPPQVISSL RSISSLMGAF SGSCRPKINP LTPFPGFYPC SEIEDPAEKG
     DRKLNKGLNR NSLPTPQLRR SSGTSGLLPV EQSSRWDRNN GKRPHQEFGI SSQGCYLNGP
     FNSNLLTIPK QRSSSVSLTH HVGLRRAGVL SSLSPVNSSN HGPVSTGSLT NRSPIEFPDT
     ADFLNKPSVI LQRSLGNAPN TPDFYQQLRN SDSNLCNSCG HQMLKYVSTS ESDGTDCCSG
     KSGEEENIFS KESFKLMETQ QEEETEKKDS RKLFQEGDKW LTEEAQSEQQ TNIEQEVSLD
     LILVEEYDSL IEKMSNWNFP IFELVEKMGE KSGRILSQVM YTLFQDTGLL EIFKIPTQQF
     MNYFRALENG YRDIPYHNRI HATDVLHAVW YLTTRPVPGL QQIHNGCGTG NETDSDGRIN
     HGRIAYISSK SCSNPDESYG CLSSNIPALE LMALYVAAAM HDYDHPGRTN AFLVATNAPQ
     AVLYNDRSVL ENHHAASAWN LYLSRPEYNF LLHLDHVEFK RFRFLVIEAI LATDLKKHFD
     FLAEFNAKAN DVNSNGIEWS NENDRLLVCQ VCIKLADING PAKVRDLHLK WTEGIVNEFY
     EQGDEEANLG LPISPFMDRS SPQLAKLQES FITHIVGPLC NSYDAAGLLP GQWLEAEEDN
     DTESGDDEDG EELDTEDEEM ENNLNPKPPR RKSRRRIFCQ LMHHLTENHK IWKEIVEEEE
     KCKADGNKLQ VENSSLPQAD EIQVIEEADE EE
//
